Overweight and obesity have become a dangerous disease requiring multiple interventions, treatment and preventions. In women of reproductive age, obesity is one of the most common medical conditions. Among others, obese state is characterized by low‐grade systemic inflammation and enhanced oxidative stress. Increased maternal body mass index might amplify inflammation and reactive oxygen species production, which is associated with unfavourable clinical outcomes that affect both mother and child. Intrauterine growth retardation, preeclampsia, or gestational diabetes mellitus are examples of the hampered maternal and foetoplacental unit interactions. Visfatin is the obesity‐related adipokine produced mainly by the visceral adipose tissue. Visfatin affects glucose homeostasis, as well as the regulation of genes related to oxidative stress and inflammatory response. Here, we review visfatin interactions in pregnancy‐related disorders linked to obesity. We highlight the possible predictive and prognostic value of visfatin in diagnostic strategies on gravidas with obesity.

中文翻译：

---

肥胖妇女中的脂肪因子visfatin可以成为妊娠相关疾病的新标志吗？

超重和肥胖已成为一种危险疾病，需要多种干预，治疗和预防措施。在育龄妇女中，肥胖是最常见的医学病症之一。肥胖状态的特征是低度全身性炎症和氧化应激增强。孕产妇体重指数升高可能会加剧炎症和活性氧的产生，这与影响母亲和儿童的不良临床结果有关。宫内生长迟缓，先兆子痫或妊娠糖尿病是阻碍母体和胎盘单位相互作用的例子。Visfatin是与肥胖相关的脂肪因子，主要由内脏脂肪组织产生。Visfatin影响葡萄糖稳态，以及与氧化应激和炎症反应相关的基因的调控。在这里，我们回顾了与肥胖相关的妊娠相关疾病中的visfatin相互作用。我们强调了visfatin在肥胖型妊娠孕妇诊断策略中可能的预测和预后价值。